10.09.2026 3:00 PM - 4:00 PM BST
Webinar
Event Host
Paul Craddy & Lauren Boland
Event Description

Building on our previous deep dive into the first JCA report, this webinar will move from understanding the reports to applying the learnings. By looking holistically across all JCA reports published to date, we will identify practical lessons and considerations to help teams prepare for future launches and JCA submissions.
The first JCAs are now providing real-world evidence of how the new EU HTA process is working in practice. Join Remap Consulting to understand what these early assessments are telling us and what manufacturers should do next.

In this webinar, we will:

  • Identify the emerging lessons from the first JCAs, including recurring patterns, challenges and differences between assessments
  • Explore what the first reports tell us about evidence expectations, including PICO strategy, direct and indirect comparative evidence, methodological scrutiny and requests for additional analyses
  • Assess the practical implications for manufacturers, including submission strategy, evidence planning, internal resourcing and preparation for future JCAs
  • Examine what happens after JCA, including how Member States are beginning to integrate JCA outputs into national HTA and reimbursement processes
  • Consider whether JCA is delivering on its objectives and where important uncertainties remain as implementation develops
  • Highlight what manufacturers need to watch next and the actions teams can take now to strengthen readiness for upcoming submissions

Attend to move beyond JCA theory and understand how the emerging evidence can inform your next submission and wider European market access strategy.

Register Today

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.